Description of Medical ServiceImlifidase is a treatment used to prevent the body from rejecting a newly transplanted kidney. It is used before transplantation in people who have antibodies against the donor kidney and are considered ’highly sensitised’ based on a positive crossmatch test. It is a desensitisation treatment, used to convert people from crossmatch positive, to negative and therefore reducing the likelihood of the recipient's body rejecting the donated kidney.
Description of Medical ConditionEnd-stage kidney disease is defined by partial or completely failed kidney function. Patients require regular dialysis or a kidney transplant for survival.
Reason for ApplicationHighly Specialised Therapy- National Health Reform Agreement
Medical Service TypeTherapeutic technology
Previous Application Number/sNot Applicable
Application FormApplication Form (PDF 2033 KB)
Application Form (Word 1634 KB)
Consultation SurveyConsultation Survey (PDF 658 KB)
Consultation Survey (Word 27 KB)
PASC consultation closes 4 November 2022
MSAC consultation TBA – please subscribe to the MSAC Email Bulletin to be notified when consultation opens for this application
For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process